MedTrace Logo

The Unhide™ Project: Economic Impact Study of IVIG Treatment for PANS

NCT06818656 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2025-09-12

No results posted yet for this study

Summary

The Economic Impact Study of IVIG treatment for PANS is a part of the Unhide™ Project, which is a research initiative developed by the Brain Inflammation Collaborative. Specifically, the Unhide™ project is a collection of investigations with the overall goal of better understanding the problems with thinking and mood that can sometimes be symptoms of conditions like autoimmune disease, infection-associated chronic conditions like Long COVID, ME/CFS, PANDAS, PANS, and other illnesses. Your contribution to this research will allow us to better describe these symptoms and understand what causes them, how they develop, and how they can best be treated and prevented.

This study seeks to assess how PANDAS/PANS affects the financial well-being of families who pursue IVIG treatment, as well as the overall health and quality of life of children with the condition. By gathering data through this survey, we aim to gain important insights into the economic consequences of treating - or not treating - PANS with IVIG, including how it impacts parents' ability to work and children's ability to attend school.

Key Eligibility Criteria

* Aged 2-89, U.S. resident, fluent in English, and have access to computer and/or smartphone
* Suspected or confirmed diagnosis of PANS/PANDAS
* Have received IVIG OR have sought and/or been prescribed IVIG but have not received it

Conditions

  • PANDAS
  • PANS
  • PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
  • Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
  • Pediatric Acute-Onset Neuropsychiatric Syndrome
  • Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections

Sponsors & Collaborators

Eligibility

Min Age
2 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-06-19
Completion
2025-06-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06818656 on ClinicalTrials.gov